Client News

Formycon AG: FYB202/Otulfi ® (ustekinumab-aauz), a Biosimilar to Stelara®, Launched in the United States and the European Union

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Affluent Medical Appoints Liane Teplitsky – a Senior Executive in the Medical Device Industry – as a New Member of the Board of Directors

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Formycon Receives Regulatory Approval in the UK for FYB203 (Aflibercept), a Biosimilar to Eylea®, under the Brand Name AHZANTIVE®

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Mainz Biomed Expands into Switzerland with labor team w

Formycon AG Presents Clinical Data on Ustekinumab Biosimilar FYB202 at the ECCO Congress in Berlin

MIG Capital Navigates a Demanding Market Environment in 2024 and Looks Ahead to 2025 with Cautious Optimism